Trulance (Plecanatide) Patent Expiration, LOE Window & CMS Spending

Trulance (Plecanatide) by Bausch Health: FDA Orange Book core substance LOE 2034-06-05, 0 AB generics, $167.3M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN208745 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-06-05
Last Listed Patent or Exclusivity Date2034-06-05
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$167.3M
2024 Medicare Part D Spend$123.2M
2024 Medicaid Spend$44.0M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 23.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.